Banque Pictet & Cie SA Has $130.27 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Banque Pictet & Cie SA reduced its holdings in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 0.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,132,974 shares of the company's stock after selling 22,425 shares during the quarter. Moderna comprises 0.9% of Banque Pictet & Cie SA's portfolio, making the stock its 16th biggest holding. Banque Pictet & Cie SA owned approximately 0.81% of Moderna worth $130,269,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Exchange Traded Concepts LLC lifted its holdings in shares of Moderna by 164.0% during the third quarter. Exchange Traded Concepts LLC now owns 17,558 shares of the company's stock worth $1,173,000 after buying an additional 10,907 shares during the last quarter. Swedbank AB increased its position in Moderna by 149.6% during the third quarter. Swedbank AB now owns 85,099 shares of the company's stock worth $5,687,000 after acquiring an additional 51,000 shares during the period. Vontobel Holding Ltd. raised its stake in Moderna by 148.2% during the 3rd quarter. Vontobel Holding Ltd. now owns 116,088 shares of the company's stock valued at $7,758,000 after purchasing an additional 69,313 shares during the last quarter. Paragon Capital Management Inc. boosted its holdings in Moderna by 97.4% in the 3rd quarter. Paragon Capital Management Inc. now owns 10,007 shares of the company's stock valued at $669,000 after purchasing an additional 4,937 shares during the period. Finally, Probity Advisors Inc. grew its position in Moderna by 15.8% in the 3rd quarter. Probity Advisors Inc. now owns 4,844 shares of the company's stock worth $324,000 after purchasing an additional 661 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MRNA. Barclays lowered shares of Moderna from an "overweight" rating to an "equal weight" rating and cut their price objective for the company from $111.00 to $45.00 in a research report on Tuesday. Piper Sandler reiterated an "overweight" rating and issued a $69.00 price objective (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. Leerink Partners decreased their price objective on Moderna from $31.00 to $27.00 and set an "underweight" rating on the stock in a report on Thursday, January 16th. Hsbc Global Res upgraded Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Finally, The Goldman Sachs Group downgraded shares of Moderna from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $99.00 to $51.00 in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $61.58.

Moderna Price Performance

MRNA stock traded up $2.73 during midday trading on Tuesday, reaching $35.72. 18,950,644 shares of the company's stock traded hands, compared to its average volume of 13,056,006. The company has a 50-day simple moving average of $38.61 and a two-hundred day simple moving average of $53.82. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 1-year low of $29.25 and a 1-year high of $170.47. The company has a market cap of $13.75 billion, a price-to-earnings ratio of -6.14 and a beta of 1.59.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 2,664 shares of company stock worth $115,210. 15.70% of the stock is owned by corporate insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.